Axsome Therapeutics, Inc. Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc.

AXSM

주식 순위 #2358
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to... Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
주가
$157.20
마지막 동기화: 2026-10-21
시가총액
$8.23B
변동 (1일)
-1.49%
변동 (1년)
21.18%
국가
US
거래 Axsome Therapeutics, Inc. (AXSM)

카테고리

Healthcare
Axsome Therapeutics, Inc. (AXSM)의 주가 이력
최고 종가: $166.68 (2026-10-01 기준)

최저 종가: $8.99 (2015-11-01 기준)
Axsome Therapeutics, Inc.의 주가 이력 (2015 ~ 2026)
연간 주가 성과
연도 성과
2026 (TTM) 25.48%
2025 62.10%
2024 26.95%
2023 -4.24%
2022 118.74%
2021 -56.59%
2020 11.03%
2019 2,538.67%
2018 -44.64%
2017 -23.67%
2016 -25.67%
2015 0.00%
유사 기업 또는 경쟁사의 주가
회사 주가 변동률 1년% 국가
$527.18 23.62%
US
$251.29 835.90%
US
$137.83 -3.78%
AU
$890.85 9.42%
NL
$763.55 8.53%
CH